ELBA

Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complimentary approach for tissue biopsies. The European Liquid Biopsy Academy (ELBA) is an Innovative Training Network that will educate early stage researchers with the skills to circumvent the obstacles currently hampering effective development and commercialisation of liquid biopsy approaches. It will make scientific advances towards widespread implementation of blood-based diagnostics tests, create a sustainable network to foster long-term multidisciplinary relationships to accelerate clinical translation of blood-based diagnostics tests and publish a roadmap to liquid biopsy test development. The project will run from January 2018 until December 2021.

ECPC's role

The European Cancer Patient Coalition will contribute to the training courses by offering expertise in patient involvement, sitting in the Project Advisory Board, and using its communication channels to share information about the project. A representative of the European Cancer Patient Coalition will attend each annual meeting and deliver a presentation on the important role that people with cancer play in research.  The European Cancer Patient Coalition will also participate in workshops on communicating complex research results to a public audience, understanding the patient perspective, and on scientific writing.

Contact Points

ECPCIsabelle Manneh-Vangramberen,  ECPC Head of Health and Research Programmes


Funding

EU Flag 

ELBA is funded by the Marie Skłodowska-Curie Actions: a part of the EU Horizon 2020 Programme, Grant Agreement N°  765492.